Evaluating Dalbavancin Suppression Therapy in Patients at High Risk for Recurrent Infections

Read full story on ncbi.nlm.nih.gov
Share
Evaluating Dalbavancin Suppression Therapy in Patients at High Risk for Recurrent Infections
AI disclosure

Summary

This multicenter cohort included the largest sample size of dalbavancin SAT to date, employed across diverse infections with substantial heterogeneity in dosing...

Original reporting

Open original source

Related coverage

Read full article on ncbi.nlm.nih.gov